



SUNTAR ECO-CITY LIMITED

Condensed interim consolidated financial statements  
For the six months and full year ended 31 December 2025

## Table of Contents

A. Condensed Interim Consolidated Statement of Comprehensive Income .....	3
B. Condensed Interim Statements of Financial Position .....	4
C. Condensed Interim Statements of Changes in Equity .....	5
D. Condensed Interim Consolidated Statement of Cash Flows .....	6
E. Notes To The Condensed Interim Consolidated Financial Statements. ....	7
F. Other information required by listing rule appendix 7.2 .....	13

## A. Condensed Interim Consolidated Statement of Comprehensive Income

	Group		+ / (-) %	Group		+ / (-) %
	2 <sup>nd</sup> half year ended 31-Dec 2025 RMB'000	2 <sup>nd</sup> half year ended 31-Dec 2024 RMB'000		Full year ended 31-Dec 2025 RMB'000	Full year ended 31-Dec 2024 RMB'000	
<b>Revenue</b>	4,943	4,349	13.7	6,230	10,243	(39.2)
Cost of sales	<u>(4,310)</u>	<u>(3,995)</u>	7.9	<u>(5,209)</u>	<u>(9,569)</u>	(45.6)
<b>Gross profit</b>	633	354	78.8	1,021	674	51.5
Other operating income	858	1,117	(23.2)	1,072	1,425	(24.8)
Write back of payables	3,693	2,000	84.7	3,693	2,000	84.7
Administrative expenses	(1,680)	(1,785)	(5.9)	(3,481)	(3,186)	9.3
Selling and distribution expenses	(288)	(258)	11.6	(487)	(449)	8.5
Other operating expenses	(229)	(142)	61.3	(229)	(142)	61.3
Share of (loss)/profit of associates	<u>(4,088)</u>	<u>6,123</u>	n.m.	<u>(658)</u>	<u>8,109</u>	n.m.
<b>(Loss)/Profit before taxation</b>	(1,101)	7,409	n.m.	931	8,431	(89.0)
Tax expense	<u>(180)</u>	<u>(118)</u>	52.5	<u>(188)</u>	<u>(208)</u>	(9.6)
<b>Net (loss)/profit</b>	<u>(1,281)</u>	<u>7,291</u>	n.m.	<u>743</u>	<u>8,223</u>	(91.0)
<b>(Loss) / Profit attributable to:</b>						
Owners of the company	(1,361)	7,255	n.m.	613	8,177	(92.5)
Non-controlling interests	<u>80</u>	<u>36</u>	n.m.	<u>130</u>	<u>46</u>	n.m.
	<u>(1,281)</u>	<u>7,291</u>	n.m.	<u>743</u>	<u>8,223</u>	(91.0)
<b>Earnings per ordinary share (cent)</b>						
- Basic	<u>(2.17)</u>	<u>11.56</u>	n.m.	<u>0.98</u>	<u>13.03</u>	(92.5)
- Diluted	<u>(2.17)</u>	<u>11.56</u>	n.m.	<u>0.98</u>	<u>13.03</u>	(92.5)

n.m.= not meaningful

## B. Condensed Interim Statements of Financial Position

	Group 31/12/2025 RMB'000	Group 31/12/2024 RMB'000	Company 31/12/2025 RMB'000	Company 31/12/2024 RMB'000
<b><u>ASSETS</u></b>				
<b>Current assets</b>				
Cash and cash equivalents	59,630	57,789	187	387
Trade receivables	922	3,665	-	-
Other receivables	375	7,976	258	219
Completed properties for sale	9,064	9,421	-	-
Inventories	331	330	-	-
<b>Total current assets</b>	<b>70,322</b>	<b>79,181</b>	<b>445</b>	<b>606</b>
<b>Non-current assets</b>				
Right-of-use asset	12,658	12,930	-	-
Property, plant and equipment	525	345	-	-
Subsidiaries	-	-	131,406	131,406
Associate	42,153	42,811	-	-
Deferred tax asset	292	292	-	-
<b>Total non-current assets</b>	<b>55,628</b>	<b>56,378</b>	<b>131,406</b>	<b>131,406</b>
<b>Total assets</b>	<b>125,950</b>	<b>135,559</b>	<b>131,851</b>	<b>132,012</b>
<b><u>LIABILITIES AND EQUITY</u></b>				
<b>Current liabilities</b>				
Trade payables	514	6,336	-	-
Other payables	24,286	29,005	23,715	21,490
Income tax payable	1,416	1,227	-	-
<b>Total current liabilities</b>	<b>26,216</b>	<b>36,568</b>	<b>23,715</b>	<b>21,490</b>
<b>Capital and reserves</b>				
Share capital	162,713	162,713	162,713	162,713
Statutory reserves	1,225	1,154	-	-
Accumulated losses	(64,507)	(65,049)	(54,577)	(52,191)
<b>Equity attributable to owners of the Company</b>	<b>99,431</b>	<b>98,818</b>	<b>108,136</b>	<b>110,522</b>
<b>Non-controlling interest</b>	<b>303</b>	<b>173</b>	<b>-</b>	<b>-</b>
<b>Total equity</b>	<b>99,734</b>	<b>98,991</b>	<b>108,136</b>	<b>110,522</b>
<b>Total liabilities and equity</b>	<b>125,950</b>	<b>135,559</b>	<b>131,851</b>	<b>132,012</b>

### C. Condensed Interim Statements of Changes in Equity

	Share capital RMB'000	Statutory reserves RMB'000	Accumulated losses RMB'000	Total RMB'000	Non- controlling interest RMB'000	Total equity RMB'000
<b>Group</b>						
Balance as at 1 January 2025	162,713	1,154	(65,049)	98,818	173	98,991
Profit for the year, representing total comprehensive income for the year	-	-	613	613	130	743
Transfer to statutory reserves	-	71	(71)	-	-	-
Balance as at 31 December 2025	<u>162,713</u>	<u>1,225</u>	<u>(64,507)</u>	<u>99,431</u>	<u>303</u>	<u>99,734</u>
Balance as at 1 January 2024	162,713	1,102	(73,169)	90,646	122	90,768
Profit for the year, representing total comprehensive income for the year	-	-	8,177	8,177	46	8,223
Transfer to statutory reserves	-	52	(57)	(5)	5	-
Balance as at 31 December 2024	<u>162,713</u>	<u>1,154</u>	<u>(65,049)</u>	<u>98,818</u>	<u>173</u>	<u>98,991</u>

	Share capital RMB'000	Statutory reserves RMB'000	Accumulated losses RMB'000	Total equity RMB'000
<b>Company</b>				
Balance as at 1 January 2025	162,713	-	(52,191)	110,522
Loss for the year, representing total comprehensive loss for the year	-	-	(2,386)	(2,386)
Balance as at 31 December 2025	<u>162,713</u>	<u>-</u>	<u>(54,577)</u>	<u>108,136</u>
Balance as at 1 January 2024	162,713	-	(50,053)	112,660
Loss for the year, representing total comprehensive loss for the year	-	-	(2,138)	(2,138)
Balance as at 31 December 2024	<u>162,713</u>	<u>-</u>	<u>(52,191)</u>	<u>110,522</u>

## D. Condensed Interim Consolidated Statement of Cash Flows

	Group	
	FY2025	FY2024
	RMB'000	RMB'000
<b>Operating activities:</b>		
Profit before taxation	931	8,431
Adjustments for:		
Depreciation of property, plant and equipment	124	58
Interest income	(869)	(812)
Depreciation of right-of-use asset	272	272
Write-back of payables	(3,693)	(2,000)
Impairment loss on development property for sale	229	-
Write off of property, plant and equipment	-	116
Write off of inventory	-	28
Share of loss/(profit) of associate	658	(8,109)
Operating (loss) before working capital changes	(2,348)	(2,016)
Change in trade receivables	2,743	(2,077)
Change in inventories	(1)	(36)
Change in other receivable	1	171
Change in completed properties for sale	128	92
Change in trade payables	(2,129)	1,888
Change in other payables and accruals	(6,700)	6,334
<b>Cash (used in)/generated from operations</b>	(8,306)	4,356
Interest received	869	812
Income tax paid	-	(110)
<b>Net cash (used in)/generated from operating activities</b>	(7,437)	5,058
<b>Investing activities:</b>		
Purchase of property, plant and equipment	(304)	(133)
Repayment from an associate	7,600	12,000
<b>Net cash generated from investing activities</b>	7,296	11,867
<b>Financing activities</b>		
Receipt of advances from a director, representing net cash generated from financing activity	1,982	2,211
<b>Net cash generated from financing activities</b>	1,982	2,211
Net increase in cash and cash equivalents	1,841	19,136
Cash and cash equivalents at beginning of financial year	57,789	38,653
<b>Cash and cash equivalents at end of financial year</b>	59,630	57,789

## **E. Notes To The Condensed Interim Consolidated Financial Statements**

### **1. Corporate Information**

Suntar Eco-city Limited (the "Company") is incorporated and domiciled in Singapore and whose shares are publicly traded on the Mainboard of the Singapore Exchange.

These condensed interim consolidated financial statements as at and for the six months and full year ended 31 December 2025 comprise the Company and its subsidiaries (collectively, the Group).

The principal activities of the Group are:

- (a) Property Development
- (b) Health and Nutrition

### **2. Basis of Preparation**

The condensed interim financial statements for the six months and full year ended 31 December 2025 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2024.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Renminbi which is the Company's functional currency.

#### **2.1 New and amended standards adopted by the Group**

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

#### **2.2 Use of Judgements And Estimates**

In preparing the condensed interim financial statements, management has made judgements, estimates, and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expenses. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2024.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

### **3. Seasonal Operations**

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

#### 4. Segment Information

The group has two reportable segments, as described below, which are the Group's strategic business unit. The Operating businesses are organized and managed separately according to the nature of the product provided, with each segment representing a strategic business unit that offers different products and serves different markets.

The Group is organized into two main operating business segments, namely:

1. Health & Nutrition
2. Property Development

#### 4.1 Reportable segments

##### Segment revenues and results

	<u>Health &amp; Nutrition</u>		<u>Property development</u>		<u>Unallocated</u>		<u>Total</u>	
	6 months ended 31-Dec 2025	6 months ended 31-Dec 2024	6 months ended 31-Dec 2025	6 months ended 31-Dec 2024	6 months ended 31-Dec 2025	6 months ended 31-Dec 2024	6 months ended 31-Dec 2025	6 months ended 31-Dec 2024
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
<b>Segment revenue:</b>								
External customers	4,831	4,239	112	110	-	-	4,943	4,349
<b>Segment result:</b>								
Segment result	217	89	3,982	2,032	(1,212)	(835)	2,987	1,286
Share of profit in associate							(4,088)	6,123
Tax expense							(180)	(118)
<b>Profit for the period</b>							(1,281)	7,291

	<u>Health &amp; Nutrition</u>		<u>Property development</u>		<u>Unallocated</u>		<u>Total</u>	
	Full year ended 31-Dec 2025	Full year ended 31-Dec 2024	Full year ended 31-Dec 2025	Full year ended 31-Dec 2024	Full year ended 31-Dec 2025	Full year ended 31-Dec 2024	Full year ended 31-Dec 2025	Full year ended 31-Dec 2024
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
<b>Segment revenue:</b>								
External customers	6,118	10,133	112	110	-	-	6,230	10,243
<b>Segment result:</b>								
Segment result	240	58	3,735	2,080	(2,386)	(1,816)	1,589	322
Share of profit in associate							(658)	8,109
Tax expense							(188)	(208)
<b>Profit for the year</b>							743	8,223

#### 4.1 Reportable segments (Cont'd)

##### Segment assets, liabilities and other segment information

	<u>Health &amp; Nutrition</u>		<u>Property development</u>		<u>Unallocated</u>		<u>Total</u>	
	31/12/2025 RMB'000	31/12/2024 RMB'000	31/12/2025 RMB'000	31/12/2024 RMB'000	31/12/2025 RMB'000	31/12/2024 RMB'000	31/12/2025 RMB'000	31/12/2024 RMB'000
<b>Assets:</b>								
Segment assets	40,205	40,902	85,558	94,207	187	450	125,950	135,559
<b>Liabilities:</b>								
Segment liabilities	646	2,790	1,615	12,016	23,955	21,762	26,216	36,568

#### 4.2 Disaggregation of Revenue

The Group derives revenue from the transfer of goods at a point in time in the People's Republic of China.

	<b>Group</b>			
	6 months ended 31 December 2025 RMB'000	6 months ended 31 December 2024 RMB'000	Full year ended 31 December 2025 RMB'000	Full year ended 31 December 2024 RMB'000
Timing of revenue recognition				

##### At a point of time:

Sale of completed properties	112	110	112	110
Sale of health and nutrition products	4,831	4,239	6,118	10,133
<b>Total</b>	<b>4,943</b>	<b>4,349</b>	<b>6,230</b>	<b>10,243</b>

#### 4.3 A breakdown of sales

		<b>Group</b>		<b>Increase / (decrease) %</b>
		<b>Full year ended 31/12/2025 RMB'000</b>	<b>Full year ended 31/12/2024 RMB'000</b>	
(a)	Sales reported for first half year	1,287	5,894	(78.2)%
(b)	Profit after tax before minority interest reported for first half year	2,024	932	n.m.
(c)	Sales reported for second half year	4,943	4,349	13.7%

(d)	Loss after tax before minority interest reported for second half year	(1,281)	7,291	n.m.
-----	---	---------	-------	------

## 5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 December 2025 and 31 December 2024

	The Group		The Company	
	31 December 2025	31 December 2024	31 December 2025	31 December 2024
	RMB'000	RMB'000	RMB'000	RMB'000
<b>Financial assets at amortised cost:</b>				
Cash and cash equivalents	59,630	57,789	187	387
Trade receivables	922	3,665	-	-
Other receivables	355	7,963	258	219
	<b>60,907</b>	<b>69,417</b>	<b>445</b>	<b>606</b>
<b>Financial liabilities at amortised cost:</b>				
Financial liabilities at amortised cost:				
Trade payables	514	3,717	-	-
Other payables	24,144	28,692	23,715	21,490
	<b>24,658</b>	<b>32,409</b>	<b>23,715</b>	<b>21,490</b>

## 6. Profit before taxation

### 6.1 Significant items

	Group			Group		
	2 <sup>nd</sup> half year ended 31-Dec 2025	2 <sup>nd</sup> half year ended 31-Dec 2024	+ / (-) %	Full year ended 31-Dec 2025	Full year ended 31-Dec 2024	+ / (-) %
	RMB'000	RMB'000		RMB'000	RMB'000	
<b>Other Income</b>						
Interest income	726	541	34.2	869	812	7.1
<b>Profit before taxation</b>						
Staff costs	(176)	(206)	(14.6)	(384)	(475)	(19.2)

Depreciation of right-of-use asset	(136)	(136)	-	(272)	(272)	-
Depreciation of property, plant and equipment	(86)	(48)	79.2	(124)	(58)	n.m.
Impairment on property for sale	229	-	n.m.	229	-	n.m.

## 6.2 Related party transactions

In addition to the related party information disclosed elsewhere in the financial statements, the following are transactions with related parties made at terms agreed between the parties:

### Compensation of directors and key management personnel

The remuneration of directors and other members of key management during the year was as follows:

The Group	2025	2024
	RMB'000	RMB'000
Directors' fees	<b>337</b>	316

### Purchase of health and nutrition product

During the financial year ended 31 December 2025, the Group purchased health and nutrition products of RMB 2,694,000 (2024 - RMB 7,101,000) from an associate.

### Rental income of equipment from related party

During the financial year ended 31 December 2025, the Group received rental income from a related party amounting to RMB 96,000 (2024 - RMB Nil).

### Advances from director

During the financial year ended 31 December 2025, the Group received advances from a director amounting to RMB1,982,000 (2024 - RMB 2,211,000).

### Product fee charged by a related party

During the financial year ended 31 December 2025, the Group incurred product fees charged by a related party of RMB839,000 (2024 - RMB898,000).

### Rental income from a related party

During the financial year ended 31 December 2025, the Group received rental income from a related party amounting to RMBNil (2024 - RMB171,000).

### Sales of health and nutrition products to related party

During the financial year ended 31 December 2025, the Group sold nutrition products to a related party of RMB89,000 (2024 - RMB32,000).

### Rental expenses charged by a related party

During the financial year ended 31 December 2025, the Group incurred rental expenses charged by a related party amounting to RMB17,000 (2024 - RMB17,000).

## 7. Taxation

The Group calculates the income tax expense using the statutory tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the interim consolidated statement of profit or loss are:

	Group			Group		
	2 <sup>nd</sup> half year ended 31-Dec 2025 RMB'000	2 <sup>nd</sup> half year ended 31-Dec 2024 RMB'000	+ / (-) %	Full year ended 31-Dec 2025 RMB'000	Full year ended 31-Dec 2024 RMB'000	+ / (-) %
Current tax expense	(180)	(118)	n.m	(188)	(208)	n.m

## 8. Dividends

No dividends for the full year ended 31 December 2025 (31 December 2024: RMBNil) is recommended. No dividends have been declared or recommended in line with the previous financial year practice. The group deems it appropriate to retain cash for operational purposes.

## 9. Net Asset Value

	Group 31/12/2025 RMB Cents	Group 31/12/2024 RMB Cents	Company 31/12/2025 RMB Cents	Company 31/12/2024 RMB Cents
Net asset value per ordinary share based on total number of issued shares excluding treasury shares	158.43	157.45	172.30	176.10

## 10. Loan and Borrowings

### Amount repayable in one year or less, or on demand

As at 31/12/2025		As at 31/12/2024	
Secured RMB'000	Unsecured RMB'000	Secured RMB'000	Unsecured RMB'000
Nil	21,756	Nil	19,774

### Amount repayable after one year

As at 31/12/2025		As at 31/12/2024	
Secured RMB'000	Unsecured RMB'000	Secured RMB'000	Unsecured RMB'000
Nil	Nil	Nil	Nil

## 11. Share Capital

	As at 31 December 2025	As at 31 December 2024
Total number of issued shares	<u>62,759,999</u>	<u>62,759,999</u>

There are no treasury shares as at 31 December 2025 and 31 December 2024.

## 12. Subsequent Events

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

## F. Other information required by listing rule appendix 7.2

### 1. Review

The condensed consolidated statement of financial position of Suntar Eco-city Limited and its subsidiaries as at 31 December 2025 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the full year then ended and certain explanatory notes have not been audited or reviewed.

### 2. Review of performance of the Group

#### Income Statement

The Group's revenue has decreased by RMB 4.01 million to RMB 6.23 million for the year ended 31 December 2025 compared to the corresponding period in 2024. The Health and Nutrition segment contributed RMB 6.12 million, while the Property Development segment generated RMB 0.11 million. In the Property Development segment, revenue was mainly attributable to the sale of car park units at the Lanjun project. In the Health and Nutrition segment, revenue consisted of RMB 3.36 million from health supplements and RMB 2.76 million from bottled water. In comparison, the Health and Nutrition segment in 2024 recorded RMB 7.55 million from health supplements and RMB 2.58 million from bottled water. The decline in health supplement sales this year was primarily due to continued challenging market conditions and intensified competition in the health supplements market. The Group will continue to monitor market developments and explore opportunities to broaden its product offerings and enhance its competitiveness in response to evolving industry dynamics.

The Group's overall gross profit margin increased to 16% in 2025 from 7% in 2024. The improvement was mainly attributable to a more favourable product mix, with a higher contribution from relatively higher-margin products within the Health and Nutrition segment, as well as improved operating leverage and cost efficiency.

Other operating income has decreased to RMB 1.07 million as compared to RMB 1.43 million in 2024. The decrease was mainly attributable to a reduction in government grants and rental income recognised during the financial year.

Other operating expenses increased from RMB 0.14 million in 2024 to RMB 0.23 million in 2025, mainly due to an impairment loss on property development for sale.

General and Administrative expenses have increased by 9% to RMB 3.48 million, primarily attributable to higher professional fees related to the property transaction recession. Selling and distribution expenses have increased by 9% to RMB 0.49 million, mainly due to shifts in product mix during the financial year.

The Group recorded a share of loss of associate of RMB 0.66 million during the financial year, as compared to a share of profit in the prior year. The decrease was mainly attributable to Wuping Hailan Real Estate Development Co., Ltd (“Hailan”) recording a loss, as profit recognition moderated following substantial handovers completed in the previous financial year. In addition, certain car park units were impaired following a valuation assessment conducted during the financial year. Hebei Huawei Health Industry Co., Ltd (“Huawei”) also reported decreased profit contribution, primarily due to lower revenue and reduced gross margins arising from its pricing and sales strategy, coupled with relatively fixed operating expenses.

As a result of the above, the Group recorded a net profit after tax of RMB 0.74 million for FY2025 as compared to a net profit after tax of RMB 8.22 million for FY2024.

### **Statement of Financial Position**

Trade receivables have decreased from RMB 3.67 million to RMB 0.92 million as of 31 December 2025. This decrease primarily due to the collection of receivable outstanding after last reporting period. Other receivables have decreased from RMB 7.98 million by RMB 7.60 million to RMB 0.38 million. It is mainly due to loan repayment in full from an associate, Hailan. Investment in associates has decreased from RMB 42.81 million to RMB 42.15 million due to the share of loss of the associate.

Completed properties available for sale decreased from RMB 9.42 million to RMB 9.06 million compared to 2024, mainly attributed to the sale and impairment of parking spaces by Wuping Lan County Real Estate Development Co., Ltd (“Wuping Lanjun”).

Trade payables have decreased from RMB 6.33 million by RMB 5.82 million to RMB 0.51 million, due to the write back of certain long-outstanding payables as income following a review, in accordance with applicable accounting standards. Such recognition was non-recurring in nature. Other payables have decreased from RMB 29.01 million by RMB 4.72 million to RMB 24.29 million, this was attributed to the settlement of payables of the property transaction during the financial year.

### **Statement of Cash Flows**

The overall net increase in cash and cash equivalents is RMB 1.84 million for the year ended 31 December 2025. It was mainly attributable to the RMB 7.60 million in loan repayments from Hailan and the receipt of interest-free advances from a Director of RMB 1.98 million, addition to settlement of payables of the property transaction.

#### **3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results**

Not applicable. No forecast or prospect statement has been previously disclosed to shareholders.

#### **4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.**

In the Health and Nutrition segment, market conditions remained challenging during the financial year. Following the Group’s efforts to optimise its product portfolio, sales performance remained under pressure amid evolving market dynamics. The Group will

continue to review its product mix and explore additional distribution channels, while monitoring industry developments closely.

In the Property Development segment, the Jiangnan project of our associate Hailan continued to make sales progress during the financial year despite the challenging conditions in the Chinese real estate market. As at the end of the financial year, the majority of the units had been sold, with handovers continuing progressively.

The Group will focus on completing the remaining phases of the project while closely monitoring market conditions.

## 5. Dividend Information

No dividends have been declared or recommended. This is in line with previous financial year practice. The group deems it appropriate to retain cash for operational purposes.

## 6. Interested person transactions

Company has no shareholders' mandate for interested person transactions.

## 7. Confirmation that the issuer has procured undertakings from all its directors and executive officers under Rule 720 (1).

The Company confirms that undertakings have been procured from all Directors and Executive Officers under Rule 720 (1).

## 8. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13) in the format below.

Name	Age	Family relationship with any director and/or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Lan Weiguang	62	Brother of Lan Chunguang, Chief Executive Officer	Non-Independent Non-Executive Chairman, 2006	Nil
Lan Chunguang	58	Brother of Lan Weiguang, Non-Independent Non-Executive Chairman	Chief Executive Officer, 2010	Nil
Lan Yihong	39	Son of Lan Weiguang, Non-Independent Non-Executive Chairman	Executive Director and Finance Director, 2015	Nil

BY ORDER OF THE BOARD

Dr Lan Weiguang  
Non-Independent Non-Executive Director

27 Feb 2026